Disruption of Cyclin Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and poly(ADP-ribose) polymerase 1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. We therefore aimed to assess the frequency and distribution of CDK12 protein expression by immunohistochemistry (IHC) in independent cohorts of breast cancer and correlate this with outcome and genomic status. We found that 21% of primary unselected breast cancers were CDK12 high, and 10.5% were absent, by IHC. CDK12 positivity correlated with HER2 positivity but was not an independent predictor of breast cancer specific survival taking HER2 status into account, however absent CDK12 protein expression significantly correlated with a triple negative phenotype. Interestingly, CDK12 protein absence was associated with reduced expression of a number of DDR proteins including ATR, Ku70/Ku80, PARP1, DNA-PK and gamma-H2AX, suggesting a novel mechanism of CDK12 associated DDR dysregulation in breast cancer. Our data suggest that diagnostic IHC quantification of CDK12 in BC is feasible, with CDK12 absence possibly signifying defective DDR function. This may have important therapeutic implications, particularly for triple negative breast cancers.
Abstract:
Disruption of Cyclin Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and poly(ADP-ribose) polymerase 1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. We therefore aimed to assess the frequency and distribution of CDK12 protein expression by immunohistochemistry (IHC) in independent cohorts of breast cancer and correlate this with outcome and genomic status. We found that 21% of primary unselected breast cancers were CDK12 high, and 10.5% were absent, by IHC. CDK12 positivity correlated with HER2 positivity but was not an independent predictor of breast cancer specific survival taking HER2 status into account, however absent CDK12 protein expression significantly correlated with a triple negative phenotype. Interestingly, CDK12 protein absence was associated with reduced expression of a number of DDR proteins including ATR, Ku70/Ku80, PARP1, DNA-PK and gamma-H2AX, suggesting a novel mechanism of CDK12 associated DDR dysregulation in breast cancer. Our data suggest that diagnostic IHC quantification of CDK12 in BC is feasible, with CDK12 absence possibly signifying defective DDR function. This may have important therapeutic implications, particularly for triple negative breast cancers.
Introduction
Breast cancer (BC) is a complex disease comprising a variety of molecular and clinically distinct subtypes. Substantial progress has been made in the management of BC mortality over the last 25 years, in part due to improved treatment modalities such as endocrine therapies, HER2-targeted therapy and combination chemotherapies (1) (2) (3) (4) . However, a proportion of sporadic primary BC remain difficult to treat. Hence, there is an urgent need for stratification and biomarker discovery within this cohort.
The CycK/CDK12 (Cyclin K/Cyclin dependent kinase 12) complex is involved in the regulation of RNA polymerase II (RNA pol II) and mRNA processing (5) (6) (7) and is known to protect normal cells from genomic instability by regulating the transcription of DNA damage response (DDR) genes (8) . Moreover, CDK12 has been postulated as a tumor suppressor gene in high-grade serous ovarian cancer (HGSOC), where it is one of the only significantly recurrently mutated genes (9) . Recurrent point mutations have been shown to abrogate the functional activity of CDK12, resulting in defects in multiple DNA repair pathways, leading to genomic instability, downregulation of some homologous recombination (HR) genes such as BRCA1, FANCI or FANCD2 (10, 11) and selective sensitivity to both platinum agents and poly (ADPribose) polymerase (PARP1/2) inhibitors (12, 13) . Indeed, recent data in HGSOC suggests that CDK12 inactivated tumors have a unique signature of genomic instability characterized by frequent mega-sized gains scattered over the genome, that is a result of numerous tandem duplications, indicative of gross defects in DNA repair (14) . In addition, recent profiling studies have also identified CDK12 mutations in primary and castration resistant prostate cancer that are mutually exclusive with other mutations in DNA repair genes (15, 16) , and akin to HGSOC, result in large tandem duplications (14) . On the other hand, in BC, CDK12 gene amplification often co-occurs with ERBB2 amplification as both are co-located at locus Ch17q12 (17, 18) , and CDK12 overexpression has been correlated with indicators of aggressive disease, suggesting that CDK12 could act as a oncogenic driver and prognostic biomarker in BC as a result of this co-location (19) .
We have previously shown that in BC, CDK12 is recurrently targeted by both DNA rearrangements (13% of HER2-amplified BC) and recurrent point mutations (2.6% of unselected BC) (13) in a similar manner to HGSOC, and that loss of CDK12 in BC models confers sensitivity to PARP1/2 inhibitors in vitro through defects in HR (12, 13) . Loss of CDK12 in BC may therefore signify response to platinum salts and/or PARP1/2 inhibitors (12,13).
Here we sought to i) investigate the distribution and frequency of CDK12 protein expression in a large series of unselected and Herceptin treated HER2-positive BC, using immunohistochemistry (IHC) and examine any correlation with survival; ii) evaluate CDK12 protein and mRNA expression with genomic alterations and iii) assess whether CDK12 would constitute an oncogenic driver in CDK12 amplified tumors.
Materials and Methods

Tissue Microarray Patient Cohorts
Unselected BC
Primary operable BC cases (n= 1,650) from the Nottingham Tenovus Primary Breast Carcinoma Series were utilized as previously described (20) (21) (22) . Patients were under the age of 71 years (median, 55 years), diagnosed between 1986 and 1999, and treated uniformly in a single institution. Clinicopathological parameters for this series are summarized in Supplementary Table S1 .
HER2-positive adjuvant trastuzumab series
The HER2-positive adjuvant trastuzumab series comprises 143 primary operable BC from patients presenting between 2003 and 2010 who received adjuvant trastuzumab (21) . HER2 status was determined according to the American Society of Clinical Oncology (ASCO) guidelines as previously described (21) .
Clinicopathological parameters for this series are summarized in Supplementary   Table S2 .
METABRIC Nottingham Breast Cancers
This series comprised 282 primary BC from Nottingham, which form part of the METABRIC cohort (23), (Supplementary Table S3 ).
Tissue Microarray (TMA) Construction
Tumor samples were arrayed as previously described (22) . Briefly, one core per tumor of 0.6 mm thickness was obtained from the most representative areas then reembedded in microarray blocks.
CDK12 Immunohistochemistry
IHC was optimized in-house, using a standard Labelled Polymer technique, on 4µm
sections of formalin-fixed paraffin embedded (FFPE) normal human tonsil; cell blocks containing the MCF7 breast cancer cell line known to express CDK12 transfected with a previously validated siRNA pool targeting CDK12 or non-targeting control and BT474 cells as a positive control (13) (Fig. 1 ). Cells were cultured as previously described (13) TMAs were assessed for nuclear CDK12 protein expression in the malignant epithelium only, using a modified Allred score (14) . Only technically sound cores containing >20% invasive tumor cells were included in the analysis. Cores were analysis as these equated to background non-specific staining. IHC staining and dichotomization of the other biomarkers included in this study were as per previous publications (24) (25) (26) (27) (28) (29) (30) . Scoring was performed blinded to the study endpoint.
Mining of public datasets
In order to corroborate our findings, we re-analysed publicly available data from The Cancer Genome Atlas (31, 32) and METABRIC (23) datasets, to ascertain the frequency of CDK12 copy number breakpoints, somatic mutations and methylation and correlate these with RNA expression levels. Low and high CDK12 gene expression were defined by using an optimal threshold for dichotomizing gene expression data as described (33 
Results
Distribution of CDK12 expression and clinicopathological correlation
In the first instance, we assessed CDK12 protein expression by IHC in 696
unselected BC samples that met the inclusion criteria (described in methods; Fig. 1 ).
Overall 73/696 tumors were absent/negative for CDK12 ( Table S4 ).
We previously identified a proportion of HER2 amplified tumors harbour out-of-frame CDK12 fusion genes. As CDK12 is known to map to the smallest region within the HER2 amplicon (17,18) these fusions are the result of an amplification breakpoint in the HER2 amplicon that converges on CDK12, disrupting its expression (13) . We also found that tumor cells with loss of CDK12 due to the presence of a breakpoint in the HER2 amplicon were sensitive to PARP1/2 inhibitors suggesting that a fraction of HER2 amplified patients with CDK12 fusions might also benefit from treatment with PARP1/2 inhibitors or platinum chemotherapy (13) . To ascertain the frequency of In summary (Supplementary Table S1 ), overall, absence of CDK12 protein expression was seen in 10.5% of unselected BC; with a similar proportion of ER+ tumours showing absent CDK12 (9.8%). Interestingly, a higher frequency of absent CDK12 was seen in TNBC within this unselected cohort (17%); however, no association with BC specific survival was seen (p= 0.577, HR= 2, 95% CI = 1.8-3.4, Log Rank (Mantel-Cox)). As expected, in all three cohorts analysed, a lower proportion of HER2-positive tumours were CDK12 absent. Rather, most HER2 positive tumours were CDK12 high (protein and mRNA). Although high CDK12
expression was associated with a worse BC specific survival in these cohorts, this association was significant in the METABRIC dataset in multivariate analysis taking HER2 status into account, but not borne out in additional datasets.
Association of CDK12 expression and amplification
We subsequently investigated the associations of CDK12 mRNA expression with Recent evidence has pointed to the role of CDK12 as a potential oncogene, given that that its amplification is associated with increased protein expression and aggressive clinical characteristics (19) and that CDK12 amplified tumors show significantly increased CDK12 protein activation (39) . To seek any evidence of oncogenic addiction to the downstream consequences of activated CDK12, we mined publicly available genetic perturbation screens in BC cell line models using validated reagents (12, 13) , to ascertain if CDK12 amplified cells were addicted to CDK12 expression and downstream signalling for their survival. Analysis of both genome-wide pooled shRNA screen data (34) and siRNA kinome screen data (35) failed to identify any association between CDK12 amplification and sensitivity to shRNA or siRNA designed to target CDK12 (Fig. 3C-D) .
Genetic mechanisms of absent CDK12 expression
Given our previous findings that disruption of CDK12 can occur as a result of an amplification breakpoint in the ERBB2 amplicon that converges on CDK12, disrupting its expression (13), we sought to confirm our findings in primary tumors from METABRIC (23) . Of all cases that showed CDK12 amplification, 14.4% (30/208) harboured a breakpoint in CDK12 that was associated with a significant reduction in CDK12 transcript levels (p< 0.0001, Mann Whitney U test; Fig. 4A ). In HER2 amplified patients, there was no significant difference in BC specific survival between patients with a breakpoint in CDK12 and those without (p= 0.32, Log Rank (MantelCox) HR= 0.9897, 95% CI= 0.5107-1.918).
To ascertain the frequency of absent CDK12 protein in tumors with copy number alterations in CDK12, we intersected the IHC data from a subset of the METABRIC Table S8 ), suggesting there are additional mechanisms that lead to CDK12 protein loss.
Absent CDK12 protein expression is associated with reduced protein expression of genes involved in DNA repair
Although predicted deleterious mutations in CDK12 did not correlate with reduced expression of DDR genes (see above), we assessed whether loss of CDK12 protein expression correlated with a reduction in the transcript expression of DNA repair proteins or biomarkers of DNA damage in the unselected series of BC cases (Table   1 ). Although no significant correlations were observed (after multiple testing correction) with DDR genes at the mRNA level (Supplementary Table S9 Table S10 ). This suggests that functional loss of CDK12 is only observed in tumors with absent CDK12 protein expression in breast cancer and not low levels of CDK12 expression.
It has been shown that in HGSOC CDK12 mutations are consistently associated with a particular genomic instability pattern characterized by hundreds of tandem duplications of up to 10 megabases (Mb) in size, dubbed the 'CDK12 TD-plus phenotype' (14) . Assessment of this pattern in both unselected and TNBC with absent CDK12 protein failed to identify any association with large numbers and sizes of tandem duplications ( Fig. 4C-D) . Together these results suggest that absent CDK12 protein in BC is associated with some defects in DNA repair related genes, however the resultant genomic scars are likely to be different to that seen in HGSOC (11) .
Discussion
In this study, we were able to analyze, for the first time, the distribution of CDK12 protein in cohorts of primary BC. We show that high CDK12 expression is significantly correlated with HER2 status and that absent CDK12 is associated with a triple-negative phenotype and disruption of proteins involved in DNA repair.
The significant correlation of CDK12 with HER2 expression in these data is not surprising, since CDK12 is known to map to the smallest region within the HER2 amplicon (17, 18) . Therefore, although we observed significant correlations with CDK12 expression and patient survival, this significance was subsequently lost when We have shown previously that a proportion of HER2-positive tumors harbor inactivating (out-of-frame) fusion genes in CDK12 that are due to a copy number breakpoint in the HER2 amplicon converging on CDK12, resulting in a significant decrease in both transcript and protein levels (13) . Furthermore, cell lines with breakpoints in CDK12 that result in loss of protein expression are sensitive to PARP1/2 inhibitor therapy, due to impaired HR mediated DNA repair (13) . By assessing the distribution of CDK12 protein expression in CDK12 amplified breast cancers in the METABRIC cohort, we identified 14% that were CDK12 absent.
Moreover, of the tumors with a breakpoint in CDK12, 33% had absent CDK12 protein expression. Whilst the numbers we were able to assess are small, this nevertheless suggests a proportion of HER2 positive patients show absent CDK12 protein as a result of both copy number breakpoints and additional mechanisms. Overall, our data suggest there may be a small proportion of HER2-positive patients that may benefit from treatment with DNA damage response targeted therapies such as PARP1/2 inhibitor therapy.
Recent data in HGSOC has shown that CDK12 point mutations inactivate gene expression subsequently abrogating HR DNA repair pathways (10, 11) . Although in our study CDK12 mutations did not themselves correlate with decreased expression of DNA repair genes (perhaps due to residual CDK12 activity, given some of these are not associated with loss of heterozygosity), we show that BC with absent CDK12
protein show down-regulation of a number of genes involved in functional HR DNA repair at the protein level, suggesting that absent CDK12 protein in BC may also be associated with HR defects. Although we were unable to assess all proteins known to be dysregulated in CDK12 mutant HGSOC such as RAD51, FANCI and FANCD2, it is reasonable to postulate that CDK12 may have other targets, including DNA repair proteins themselves, phosphorylation of which is required for protein stability.
Lack of any observed associations at the mRNA level, may be due to small numbers in the study, however, our observed associations warrant further investigation in larger cohorts. Recent evidence in HGSOC points to a unique signature of genomic instability in CDK12 mutated tumors that is indicative of gross defects in DNA repair characterized by tens to hundreds of large tandem duplications scattered throughout the genome, although this was not observed in CDK12 mutated breast cancers (14) .
Consistent with this, we observed no correlation with large tandem duplications of neither all BC nor TNBC specifically. It is intriguing however that we observed absent CDK12 protein in 17% of TNBC from the unselected primary BC analyzed in this study. Of course, this could be a consequence of the small number of cases included, however CDK12 inactivation may play a role in a subset of TNBC's possibly through mechanisms distinct from those observed in HGSOC.
In 
